Urology

Researchers unable to conclude the two strategies produce equivalent results

Check out our review of recent medical stories in the media - Top Story: Trying to send your doctor an e-mail? Good luck with that. Read this and

TORONTO | The Ontario Institute for Cancer Research is collaborating with pharmaceutical company Janssen to find and test new biomarkers to identify patients with hormone-resistant prostate cancer at high risk for disease progression and biomarkers of response to therapy.

Safety trial of MRI-guided ultrasound ablation launched in Ontario

Beta-3-adrenoceptor agonist offers alternative to decades-old treatments

Study shows no impact on detection of clinically significant findings

OTTAWA and MONTREAL | The Canadian Cancer Survivor Network has expressed disappointment that Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) did not recommend cabazitaxel, a chemotherapy shown to have a significant survival benefit for men with metastatic hormone-refractory prostate cancer who are not responding to other treatments.